Researchers at Integra Therapeutics along with Pompeu Fabra University and the Center for Genomic Regulation have designed synthetic proteins via generative AI that exceed natural proteins in genome editing efficiency. These novel proteins were experimentally validated, demonstrating enhanced targeted nucleases for improved gene modification. This breakthrough exemplifies AI’s transformative potential in protein engineering to advance gene therapy and precision medicine.